Cara Therapeutics, Inc. (NASDAQ:CARA) CEO Derek T. Chalmers sold 16,000 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the completion of the transaction, the chief executive officer now owns 1,066,292 shares of the company’s stock, valued at approximately $13,499,256.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) opened at $12.33 on Friday.
Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.03). During the same period in the previous year, the business posted ($0.42) earnings per share. equities research analysts predict that Cara Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.
A number of research firms recently weighed in on CARA. Raymond James Financial, Inc. decreased their price target on Cara Therapeutics from $28.00 to $25.00 and set a “market perform” rating for the company in a research report on Thursday, August 3rd. Piper Jaffray Companies set a $27.00 price target on Cara Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 5th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a research report on Friday, August 4th. BidaskClub lowered Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Cara Therapeutics in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Cara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.46.
Institutional investors have recently made changes to their positions in the company. Gotham Asset Management LLC acquired a new stake in shares of Cara Therapeutics during the 2nd quarter valued at about $448,000. Vanguard Group Inc. lifted its holdings in shares of Cara Therapeutics by 20.0% during the 1st quarter. Vanguard Group Inc. now owns 943,627 shares of the biopharmaceutical company’s stock valued at $17,353,000 after buying an additional 156,958 shares during the last quarter. Swiss National Bank acquired a new stake in shares of Cara Therapeutics during the 2nd quarter valued at about $651,000. FMR LLC lifted its holdings in shares of Cara Therapeutics by 27.7% during the 2nd quarter. FMR LLC now owns 1,198,812 shares of the biopharmaceutical company’s stock valued at $18,450,000 after buying an additional 260,036 shares during the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Cara Therapeutics during the 1st quarter valued at about $750,000. Institutional investors and hedge funds own 61.06% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
What are top analysts saying about Cara Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc. and related companies.